8-K
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 8, 2023
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Exact name of registrant as specified in its charter)
| Israel | 001-16174 | 00-0000000 |
|---|---|---|
| (State or Other Jurisdiction<br> <br>of Incorporation) | (Commission<br> <br>File Number) | (IRS Employer<br> <br>Identification No.) |
| 124 Dvora Hanevi’a Street<br> <br>Tel Aviv 6944020, Israel | ||
| --- | ||
| (Address of Principal Executive Offices, including Zip Code) |
+972-3-914-8213
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br>Symbol(s) | Name of each exchange<br> <br>on which registered |
|---|---|---|
| American Depositary Shares, each representing one Ordinary Share | TEVA | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| ITEM 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements with Certain Officers |
|---|
On May 8, 2023, Jean-Michel Halfon informed Teva Pharmaceutical Industries Ltd. (“Teva”) that in light of personal reasons, he will resign from Teva’s Board of Directors (“Board”), effective immediately. Mr. Halfon has served as a director on the Board since 2014, as chair of the Board’s HR and Compensation Committee and more recently as chair of the Compliance Committee.
As provided in Teva’s Notice of 2023 Annual Meeting of Shareholders and Proxy Statement, filed with the Securities and Exchange Commission on April 19, 2023, Mr. Halfon is not standing for re-election at Teva’s upcoming annual meeting of shareholders on June 15, 2023.
Mr. Halfon’s decision to resign as a director was not due to any disagreements with Teva.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | |||
|---|---|---|---|
| Date: May 11, 2023 | By: | /s/ Eli Kalif | |
| Name: | Eli Kalif | ||
| Title: | Executive Vice President, Chief Financial Officer |